Antares Pharma (ATRS) Misses Q4 EPS by 1c

Antares Pharma (NASDAQ: ATRS) reported Q4 EPS of ($0.04), $0.01 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $11.8 million versus the consensus estimate of $12.53 million.

For earnings history and earnings-related data on Antares Pharma (ATRS) click here.

You May Also Be Interested In

• Stitch Fix (SFIX) Tops Q4 EPS by 4c; Offers Guidance
• Visa deposits $405M into U.S. litigation escrow, adjusting stock rates
• UBS Reiterates Buy Rating on KB Home (KBH) Amid Transition Back to Built-to-Order